{"id":343,"date":"2020-07-07T05:50:02","date_gmt":"2020-07-07T05:50:02","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=343"},"modified":"2020-07-07T05:50:02","modified_gmt":"2020-07-07T05:50:02","slug":"04-july-2020-acei-and-arb-no-significant-association-between-acei-arb-treatment-and-severe-covid-19-outcomes","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/04-july-2020-acei-and-arb-no-significant-association-between-acei-arb-treatment-and-severe-covid-19-outcomes\/","title":{"rendered":"(04 July 2020) ACEi and ARB- no significant association between ACEI\/ARB treatment and severe COVID-19 outcomes"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis<\/p>\n<p class=\"\"><a href=\"https:\/\/doi.org\/10.1007\/s11684-020-0800-y\">https:\/\/doi.org\/10.1007\/s11684-020-0800-y<\/a><\/p>\n<p class=\"\">In a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, patients on anti-hypertensive treatment with or without ACEI\/ARB was compared on their clinical characteristics and outcomes. The medical records from 702 patients were screened. Among the 101 patients with a history of hypertension and taking at least one anti-hypertensive medication, 40 patients were receiving ACEI\/ARB as part of their regimen, and 61 patients were on antihypertensive medication other than ACEI\/ARB. We observed no statistically significant differences in percentages of in-hospital mortality (28% vs. 34%, P = 0.46), ICU admission (20% vs. 28%, P = 0.37) or invasive mechanical ventilation (18% vs. 26%, P = 0.31) between patients with or without ACEI\/ARB treatment. Further multivariable adjustment of age and gender did not provide evidence for a significant association between ACEI\/ARB treatment and severe COVID-19 outcomes. Our findings confirm the lack of an association between chronic receipt of renin-angiotensin system antagonists and severe outcomes of COVID-19. Patients should continue previous anti-hypertensive therapy until further evidence is available.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis https:\/\/doi.org\/10.1007\/s11684-020-0800-y In a single-center, retrospective analysis of hospitalized adult COVID-19 patients in Wuhan, China, patients on anti-hypertensive treatment with or without ACEI\/ARB&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/04-july-2020-acei-and-arb-no-significant-association-between-acei-arb-treatment-and-severe-covid-19-outcomes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(04 July 2020) ACEi and ARB- no significant association between ACEI\/ARB treatment and severe COVID-19 outcomes&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[70,4],"tags":[29,71],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/343"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=343"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/343\/revisions"}],"predecessor-version":[{"id":344,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/343\/revisions\/344"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}